Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 08, 2022
Share
Li Kang Biomedical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 201.87 million compared to TWD 98.22 million a year ago. Revenue was TWD 201.87 million compared to TWD 98.22 million a year ago. Net income was TWD 30.43 million compared to TWD 12.41 million a year ago. Basic earnings per share from continuing operations was TWD 1.1391 compared to TWD 0.4609 a year ago. Diluted earnings per share from continuing operations was TWD 1.1304 compared to TWD 0.4609 a year ago.
For the six months, sales was TWD 303.21 million compared to TWD 191.84 million a year ago. Revenue was TWD 303.21 million compared to TWD 191.84 million a year ago. Net income was TWD 44.37 million compared to TWD 22.44 million a year ago. Basic earnings per share from continuing operations was TWD 1.6522 compared to TWD 0.8348 a year ago. Diluted earnings per share from continuing operations was TWD 1.6522 compared to TWD 0.8348 a year ago.
Li Kang Biomedical Co., Ltd. formerly BAFO TECHNOLOGIES CORP., is engaged in the manufacture and sale of computer, communication and consumer (3C) product cables and circumscribed computer peripheral products, as well as communication products. The Company offers unshielded twisted pair (UTP) cables, monitor cables, small computer system interface (SCSI) cables, universal serial bus (USB) cables, wireless hopping/mesh access points, wireless modules, and wireless vehicle communication systems, among others. The Company distributes its products within the domestic market and to overseas markets, including Europe, the Americas and the rest of Asia.
LI KANG BIOMEDICAL CO., LTD. 
